IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
about
Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRIImaging genomics in cancer research: limitations and promisesATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastomaLocal image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational statusMolecular differences between cerebral blood volume and vessel size in glioblastoma multiforme.Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study.Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma.Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology.Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.Voxel-wise analysis of dynamic F-FET PET: a novel approach for non-invasive glioma characterisationElevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomasLesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomasIdentification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
P2860
Q28067399-ADF2FEC5-821B-4A3C-97C3-ADEA82096813Q33733375-60D1F692-BB14-407F-A259-A2B14BF341D8Q37176568-8D961068-E913-4EEF-81BD-925B9190B6FBQ37298192-83552D17-F958-4524-97DA-4BAC6BFBD61CQ37339878-F253B8C2-D186-4151-BA0E-1F58E516E19EQ37677994-2F89BAA6-49FF-4D1D-B041-D23774094ADBQ37706877-530A9A2A-485E-4785-90DB-437B48C4D40AQ39685607-6E4771AD-838E-4B3D-86E5-59381CEF7CB9Q42362331-41F303A2-114D-458D-A635-F604099C84FFQ42683729-13082BA2-BDFC-47C1-BDD2-CA700B9EEBA8Q43376098-6BA43DC5-2D70-4578-8343-757D648F6562Q47162697-8024A2BF-8F6E-4360-86E0-114E2465210AQ47192935-D11E5547-2241-4A0E-94C4-D971CBDC8EE0Q47208595-B3E5C855-837B-43D7-889D-3D39E58DE192Q47605895-2AF295D0-ED4E-4AFF-9EA9-00E724B30455Q47993560-E5FEB146-CC24-48B8-815E-94EC428FA46BQ48025562-BAFB5510-BFE4-44D4-89F3-A65CD26543A8Q48167305-C687098E-CB08-4BA5-AF9F-2F913B6EB32BQ48222832-77B4B4B1-650F-4A5A-945A-54380DB5059EQ48307043-E319ABD9-DA10-414C-BCD6-71DCE8EF634EQ48663479-9AF18BDF-7B37-463D-B063-3BDE1F5094B7Q50033966-A9B6A838-8999-4CEC-A2C0-9361A10E91C6Q52584624-6C8FEB32-F3CB-4B7F-ABB0-547B85851439Q52679143-83C58491-00DB-4C11-B66F-3A9B6EA2CD7DQ54948216-F782C417-A611-4695-B096-05827AEA7606Q55457379-0291ADC3-22A8-4344-A26A-A701E0580BE5Q55457409-8B953268-6A71-4C65-B115-93501DEF8EF0Q57158891-FC0B1D06-F60A-4616-8CD1-760CC4DC8688Q58545426-B30BF85C-EE24-4F60-9C51-01D9C1EAB5ABQ58799739-5091D717-4456-4DD0-978C-EECA138D10ECQ59134257-FE23DE41-54E8-4F74-9BD3-6C4344A22543
P2860
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IDH mutation status is associa ...... rCBV imaging in human glioma.
@ast
IDH mutation status is associa ...... rCBV imaging in human glioma.
@en
type
label
IDH mutation status is associa ...... rCBV imaging in human glioma.
@ast
IDH mutation status is associa ...... rCBV imaging in human glioma.
@en
prefLabel
IDH mutation status is associa ...... rCBV imaging in human glioma.
@ast
IDH mutation status is associa ...... rCBV imaging in human glioma.
@en
P2860
P50
P356
P1433
P1476
IDH mutation status is associa ...... rCBV imaging in human glioma.
@en
P2093
Sabine Heiland
P2860
P2888
P356
10.1038/SREP16238
P407
P50
P577
2015-11-05T00:00:00Z
P5875
P6179
1047111408